Navigation Links
Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
Date:11/8/2013

(PRWEB) November 08, 2013

Drug maker Johnson & Johnson has agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the federal government has reported that there are health risks associated with use of the drug among those groups.

The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega, according to a Nov. 4 New York Times story.* The federal government alleges J&J marketed the drug to high-risk groups between 1999 and 2005, the story said, adding that part of the settlement includes J&J pleading guilty to a criminal misdemeanor for its role in promoting the drug to those groups (United States of America v. Janssen Pharmaceuticals, Inc.; 13-605; U.S. District Court for the Eastern District of Pennsylvania).

Risperdal has been shown to nearly double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

“Unfortunately, that $2.2 billion represents criminal and civil fines, not money to compensate victims,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Those injured by Johnson & Johnson’s actions should consider retaining an attorney to assist them in seeking to obtain compensation for harms allegedly suffered from use of the drug."

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn more about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/risperdal-lawsuits/heart-failure/prweb11315249.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
2. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
3. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
4. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
5. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
6. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
7. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
8. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
9. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Orders in Federal Litigations for Ethicon, American Medical Systems Lawsuits
10. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Hearing Scheduled on Remand of Stryker Hip Recall Claim to State Court
11. A Consumer Class Action Lawsuit Has Been Filed Over Allegedly Deceptive “Novarel Slim iPant,” “Flexees” Fat Destruction and Cellulite Slimming Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Pekin, IL (PRWEB) , ... February 24, 2017 , ... ... in the 7th annual “Imagine Me Beyond What You See” body image mannequin art ... Professional’s Choice will be showcased and the winner revealed at the 31st annual iaedp ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Autism ... What are the key drugs marketed for ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device ... of chronic pain, today reported financial results for the three ... 2016 Accomplishment & Highlights: Achieved revenue ... of 228% as reported, over the prior year ... 612% over the prior year International revenue ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology: